Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMA Conditioning and Haplo/MUD BMT for Upfront SAA
NCT02833805Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2016
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in aplastic anemia, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2016; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02833805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833805.